This study was designed to assess the effects of opiate treatment on the expression of Fas-associated protein with death domain (FADD) in the rat brain. FADD is involved in the transmission of Fas-death signals that have been suggested to contribute to the development of opiate tolerance and addiction. Acute treatments with high doses of sufentanil and morphine (m-agonists), , and U50488H (k-agonist) induced significant decreases (30-60%) in FADD immunodensity in the cerebral cortex, through specific opioid receptor mechanisms (effects antagonized by naloxone, naltrindole, or nor-binaltorphimine). The cannabinoid CB 1 receptor agonist WIN 55,212-2 did not alter FADD content in the brain. Chronic (5 days) morphine (10-100 mg/kg), SNC-80 (10 mg/kg), or U50488H (10 mg/kg) was associated with the induction of tachyphylaxis to the acute effects. In morphine-and SNC-80-tolerant rats, antagonistprecipitated (2 h) or spontaneous withdrawal (24-48 h) induced a new and sustained inhibition of FADD (13-50%). None of these treatments altered the densities of caspases 8/3 (including the active cleaved forms) in the brain. Pretreatment of rats with SL 327 (a selective MEK1/2 inhibitor that blocks ERK activation) fully prevented the reduction of FADD content induced by SNC-80 in the cerebral cortex (43%) and corpus striatum (29%), demonstrating the direct involvement of ERK1/2 signaling in the regulation of FADD by the opiate agonist. The results indicate that m-and d-opioid receptors have a prominent role in the modulation of FADD (opposite to that of Fas) shortly after initiating treatment. Opiate drugs (and specifically the d-agonists) could promote survival signals in the brain through inhibition of FADD, which in turn is dependent on the activation of the antiapoptotic ERK1/2 signaling pathway.
INTRODUCTION
Fas (APO-1) is a cell surface receptor glycoprotein belonging to the tumor necrosis/nerve growth factor superfamily (Nagata and Golstein, 1995) , which plays a major role in apoptosis (MacEwan, 2002) . Following trimerization of Fas after ligation with Fas-L, the receptor rapidly recruits procaspase-8 through the key adaptor protein called Fas-associated protein with death domain (FADD) (Chinnaiyan et al, 1995) that transmitts the death signal (Algeciras-Schimnich et al, 2002; Henkler et al, 2005) . FADD protein carries a death domain (DD) at its C-terminal region, involved in the binding of Fas, which also displays a single serine phosphorylation site that is essential, inter alia, for cell cycle regulation and survival/proliferation in some cells (Scaffidi et al, 2000; Zhang et al, 2004) . The N-terminal domain of FADD is called the death effector domain (DED) and is responsible for recruiting procaspase-8, which after dimerization is autoactivated to a mature enzyme with the initiation of apoptosis (Tourneur et al, 2005) . FADD is expressed in the cytoplasm and nucleus (Gómez-Angelats and Cidlowski, 2003) , but upon Fas ligation cytoplasmic FADD is rapidly recruited to the plasma membrane, where it forms, together with Fas and procaspase-8, the so-called death-inducing signaling complex (DISC) (Kischkel et al, 1995; Algeciras-Schimnich et al, 2002) . In type I cells (not dependent on mitochondrial signal amplification) (Barnhart et al, 2003) , caspase-8 directly activates downstream effector caspases (eg caspases-3/6/7), allowing cleavage of numerous substrates leading to cell death (Cohen, 1997; MacEwan, 2002) . Fasinduced death in the nervous system (Felderhoff-Mueser et al, 2000) was shown to share the same basic mechanisms with peripheral cells (Sastry and Rao, 2000) .
Besides the role of Fas/FADD in apoptosis, there are now solid evidences that also demonstrate the relevance of this system in the regulation of cell growth and differentiation (Budd, 2002; Tibbetts et al, 2003) and in regenerative responses in neurons Lambert et al, 2003) . These nonapoptotic roles for Fas/FADD are still poorly understood and may involve the activation of the ERK1/2 MAPK pathway, which is important for antiapoptotic signals (Holmström et al, 1999 (Holmström et al, , 2000 Wada and Penninger, 2004) and for the regulation of synaptic plasticity, learning, and memory (Kyosseva, 2004) .
During the last few years, various chronic effects of heroin/morphine on the structure of neurons have been interpreted to indicate that opiate drugs might induce neuronal damage after long-term exposure (see Nestler, 1996; Büttner et al, 2000; Ferrer-Alcón et al, 2000) . In this context, Fas proteins (native and glycosylated receptor, and complexes of monomers relevant in Fas signaling) were shown to be upregulated after chronic heroin and morphine treatments and heroin withdrawal in rat brain (Boronat et al, 2001; García-Fuster et al, 2003a , 2004a , which suggested a role for Fas in opiate addiction either as promoter of abnormal cell death (see Yin et al, 1999; Wang et al, 2002) or as a possible nonapoptotic signal transducer of opioid receptors (see Tegeder and Geisslinger, 2004) . To clarify this issue, the present study was designed to assess the modulation of FADD (the transmitter of Fas signal) and effector caspase-8/3 in the brain after the acute and chronic treatments with selective m-, d-, and k-opioid peptide (MOP-, DOP-, and KOP-) receptor agonists, and during the induction of opiate withdrawal in rats. Since the activation of some MAPK pathways is relevant for antiapoptotic signals (see above), the possible involvement of ERK1/2 signaling in the effect of a d-agonist on FADD was also investigated. A preliminary account of this work was given at the XXV Congress of the Spanish Society of Pharmacology (García-Fuster et al, 2003b) .
MATERIALS AND METHODS

Drug Treatment of Rats
Adult male Sprague-Dawley rats (200-250 g) were used. They were housed under controlled environmental conditions (221C, 70% humidity, and 12-h light/dark cycle) with free access to a standard diet and tap water. The rats were treated in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals (1985) and in agreement with the local ethical committee. For the acute treatments with opiate agonists, the rats received a single intraperitoneal (i.p.) or subcutaneous (s.c.) injection of sufentanil (1-30 mg/kg, s.c., 30 min, or 15 mg/kg for 30-120 min), morphine (3-100 mg/kg, i.p., 2 h), SNC-80 (a selective d-agonist, 1-10 mg/kg, i.p., 30 min, or 10 mg/kg for 30-120 min), or (À)-U50488H (a selective k-agonist, 1-10 mg/ kg, i.p., 1 h, or 10 mg/kg for 30-120 min). To assess the specificity of the opioid receptor involved, groups of rats received single doses of the nonselective antagonist naloxone (10 mg/kg, i.p.) alone (90 min) or 60 min before sufentanil (15 mg/kg), the selective d-antagonist naltrindole (5 mg/kg, i.p.) alone (60 min) or 30 min before SNC-80 (10 mg/kg), and the selective k-antagonist nor-binaltorphimine (5 mg/kg, i.p.) alone (90 min) or 30 min before (À)-U50488H (10 mg/kg). Control rats received 0.9% saline vehicle (1 ml/kg) or dimethyl sulfoxide (DMSO, 1 ml/kg, in the case of SNC-80). The animals were killed by decapitation at the indicated times. For the chronic treatment with morphine, the rats were injected i.p. three times daily during 5 days with increasing doses of the opiate (10-100 mg/kg) (Boronat et al, 2001) and killed 2 h after the last dose. After this chronic treatment, naloxone (2 mg/kg, i.p., 2 h)-precipitated withdrawal or spontaneous (24 and 48 h) opiate withdrawal was induced, which resulted in the standard behavioral reaction (data not shown; see Gabilondo and García-Sevilla, 1995; Miralles et al, 2005) . In another series of chronic experiments, groups of rats were treated with SNC-80 (10 mg/kg) or (À)-U50488H (10 mg/kg) once daily during 5 days. After these chronic treatments, naltrindole or nor-binaltorphimine (5 mg/kg, i.p., 2 h)-precipitated opiate withdrawal was induced, which resulted in a mild behavioral (k) reaction or the absence of behavioral (d) signs (data not shown; see Milanés and Laorden, 1998; Brandt et al, 2001) . Control rats received chronic 0.9% saline (1 ml/kg) or DMSO (1 ml/kg, in the case of SNC-80) in parallel. The animals were killed 30 min-2 h after the last dose (chronic saline, chronic opiate, or chronic opiate plus withdrawal) or at the times indicated after morphine withdrawal. In a final series of experiments, groups of rats received a single i.p. injection of the cannabinoid CB 1 receptor agonist WIN55,212-2 (4 and 8 mg/kg, 1 h) or were treated twice daily (i.p.) during 5 days with increasing doses of this agonist (2-8 mg/kg; rats killed 1 h after the last dose). Control rats received the appropriate vehicle (cremophor EL : ethanol : water; 1 : 1 : 18, 1 ml/kg i.p.) (see Moranta et al, 2004) . The brains were rapidly removed and specimens of the cerebral cortex and/or corpus striatum were dissected on ice, frozen in liquid nitrogen, and then stored at À801C until use.
In Vivo Effect of MEK Inhibition on d-Opioid
Receptor-Mediated Changes in FADD and MEK/ERK Activities
To assess the possible involvement of MAPK/ERK1/2 in the regulation of FADD by the d-agonist SNC-80, groups of rats were treated with the highly selective MAP/ERK kinases (MEK1/2) inhibitor SL 327 (Scherle et al, 2000) (20 mg/kg, i.p.) alone (90 min) or 60 min before SNC-80 (10 mg/kg, 30 min) to block ERK1/2 activation. Control rats received DMSO (1 ml/kg) or SNC-80 (10 mg/kg, i.p., 30 min). The animals were killed at the indicated times and the immunodensity of FADD quantitated. In this series of experiments, the effects of SNC-80, SL 327, and SNC + SL on the contents of MEK/ERK, Fas receptor proteins, and bactin were also quantitated (see below). In the MEK/ERK1/2 activation assays, equal amounts of protein were used to visualize and quantify phosphorylation of MEK1/2 and ERK1/2 (p44/42 MAP kinases) by immunoblotting essentially as described (Ferrer-Alcón et al, 2004) .
Sample Preparations, Protein Dephosphorylation and Subcellular Fractionation Experiments
Brain tissue was homogenized (1 : 15, wt/vol) in cold 50 mM Tris-HCl buffer, pH 6.8, containing 2% SDS, 1 mM EDTA, and various protease inhibitors (García-Fuster et al, 2003a) . Aliquots of total homogenate were mixed with equal volumes of electrophoresis loading buffer, boiled (denatured), and stored at À201C until use. Protein concentrations were determined by the BCA Protein Assay Reagent (Pierce Biotechnology). In addition to rat brain, mouse (cerebral cortex) and human (prefrontal cortex) brain samples were also used for the immunodetection and characterization of FADD with different anti-FADD antibodies. In some experiments, the specificity of the anti-FADD antibody (H-181) for nonphosphorylated or phosphorylated epitopes was tested on Western blots of rat brain, essentially as described (Ferrer-Alcón et al, 2000) . Briefly, brain tissue was homogenized (as above without EDTA) and centrifuged (40 000 Â g for 15 min). Aliquots of the initial homogenate (H) and the final supernatant (S2) were incubated in the absence (control) or presence of calf intestinal mucosa alkaline phosphatase (95 units, Product 79390, Sigma-Aldrich, Germany). Some samples containing the enzyme were also incubated with 100 mM sodium pyrophosphate (inhibited control). The reaction was terminated by adding 100 mM sodium pyrophosphate to control and alkaline phosphatase samples. Finally, the samples were prepared (about 40 mg protein) for SDS-PAGE and FADD immunodetection (see below). In other experiments the subcellular localization of FADD was monitored (cerebral cortex, 100 mg) using the Subcellular Proteome Extraction Kit (ProteoExtractt, Calbiochem, Germany) following the manufacturer's instructions. This method is based on the different solubility of proteins in certain subcellular compartments to yield four subproteomes enriched in cytosolic (F1), membrane/organelle (F2), nuclear (F3), and cytoskeletal proteins (F4) (AbdolzadeBavil et al, 2004) , and this procedure was also used to assess the effect of sufentanil on the content of FADD in the different compartments by Western blot analysis (15 mg protein), as described below.
Immunoblot Assays and Quantitation of Target Proteins
In routine experiments, 40 mg protein of each rat brain sample was subjected to SDS-PAGE on 10% (FADD) or 15% (caspases) polyacrylamide minigels (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were electrophoretically transferred to nitrocellulose membranes and incubated in a blocking solution (García-Fuster et al, 2003a) . The membranes were incubated overnight at 41C in blocking solution containing the appropriate primary antibody: anti-FADD (H-181) (affinity-purified rabbit polyclonal antibody raised against human FADD C-terminal 28-208 residues; dilution 1 : 5000; sc-5559, batch C-112, Santa Cruz Biotechnology, CA, USA), anti-FADD (rat) (purified mouse monoclonal antibody; dilution 1 : 1000; cat.: 558202, clone 28, batch 08738, BD Biosciences Pharmingen, San José, CA, USA), anti-FADD (human) (purified mouse monoclonal antibody; dilution 1 : 500; cat.: 610399, clone 1, BD Biosciences), anti-caspase-8 p20 (rabbit polyclonal antibody raised against human caspase-8, residues 217-350, that also reacts with the p20 cleavage form; dilution 1 : 1000; sc-7890, batch F-1604, Santa Cruz), anti-caspase-3 (rabbit polyclonal antibody raised against the full-length precursor form of human caspase-3, residues 1-277, that also reacts with the p20 cleavage form; dilution 1 : 2000; sc-7148, batch H-011, Santa Cruz), anti-caspase-3 (rabbit polyclonal antibody raised against the full-length precursor form of human caspase-3 that also reacts with the p20 cleavage form; dilution 1 : 1000, cat.: 552785, batch 11136, BD Biosciences), anti-b-actin (mouse monoclonal antibody; clone AC-15, batch No. 014K4840; dilution 1 : 10 000; Sigma Chemical Co., MO, USA), and anti-neurofilament-L (mouse monoclonal antibody; clone NR4, batch no. 109H4809; dilution 1 : 5000; Sigma). In order to test the selectivity of anti-FADD H-181 antibody with specific proteins, the antigenic peptide (sc-4701, Santa Cruz) was preincubated in excess with the antiserum to block the binding of the antibody to the specific protein species tested. Other primary antibodies used were: anti-Fas M-20 (Santa Cruz); anti-total and antiphosphorylated MEK1/2 (Cell Signaling Technology, Beverly, MA, USA), and anti-total and anti-phoshorylated ERK1/2 (Calbiochem-Novabiochem Corporation, San Diego, CA, USA) (see García-Fuster et al, 2003a; Ferrer-Alcón et al, 2004) . The secondary antibody, horseradish peroxidase-linked anti-rabbit or anti-mouse IgG, was incubated at 1 : 5000 dilution in blocking solution at room temperature for 1 h, or during 45 min for the anti-goat IgG. Immunoreactivity of target proteins was detected with the Enhanced Chemiluminiscence (ECL) Western Blot Detection system (Amersham International, Buckinghamshire, UK) and visualized by exposure to Hyperfilm ECL film (Amersham) for 30 s-60 min (autoradiograms). The autoradiograms were quantitated by densitometric scanning (GS-800 Imaging Densitometer, Bio-Rad). The amount of target proteins in brain samples of rats treated with opiate drugs was compared in the same gel with that of control rats which received saline or DMSO solution. Experiments were performed by using protein samples known to be within the linear range for immunolabeling of FADD and other target proteins (see Boronat et al, 2001 ). The quantification procedure was assessed 3-5 times in different gels (each gel with different brain samples from saline/DMSO-and drugtreated rats). Finally, percent changes in immunoreactivity with respect to control samples (100%) were calculated for each rat treated with the specific drug in the various gels and the mean value used as a final estimate. In all experiments, the content of b-actin (a cytoskeletal protein not altered by opiate treatment; Ammon et al, 2003; MarieClaire et al, 2004 ) was quantitated as a negative control.
Data Analyses and Statistics
All series of data were analyzed with the program GraphPad Prismt, version 3.0. Results are expressed as mean values7standard error of the mean (SEM). One-way ANOVA followed by Bonferroni's multiple comparison test and Student's two-tailed t-test were used for the statistical evaluations. The level of significance was chosen as po0.05.
Drugs and Chemicals
Opiate drugs (and their sources) included sufentanil HCl (Janssen-Cylag, SA, Madrid, Spain), morphine HCl and heroin HCl (Unión Químico-Farmacéutica SAE, Madrid, 
RESULTS
Immunodetection and Subcellular Localization of FADD in Brain Tissue
In Western blot analyses, the antibody H-181 (mapping at the FADD C-terminal) recognized various closely migrating bands with sizes of about 51-75 kDa from rat, mouse, and human brain (total homogenate), which represented specific FADD forms since they were not immunodetected with the preabsorbed antibody ( Figure 1a ). Similar results were obtained with two monoclonal antibodies ( Figure  1b, c) , which also immunodetected the 51-kDa form of FADD in rat brain tissue, but with a weak signal that was difficult to quantitate in routine experiments. In human brain tissue, the anti-human monoclonal antibody also detected a peptide of about 25-kDa that corresponded to Samples containing the enzyme were also incubated with 100 mM sodium pyrophosphate (IC, inhibited controls). The amount of protein loaded on the gel was 40 mg for all samples. Note that FADD dephosphorylation did not block the immunoreactivity of antibody H-181 (ie the antibody reacted with FADD independently of the state of protein phosphorylation). (e) Representative immunoblot depicting the subcellular localization of FADD in the rat cerebral cortex (F1: cytosol; F2: membrane/organelle; F3: nucleus; F4: cytoskeletal proteins; 15 mg protein for each fraction) (Subcellular Proteome Extraction Kit, ProteoExtractt). Note that FADD was mainly expressed in F1 and F3 and that the protein was not detected in the F4. The apparent molecular masses of FADD forms were determined by calibrating the blots with prestained molecular weight markers as shown on the left-hand side. In each experiment, all samples were run in the same gel.
Regulation of FADD by opiate drugs M-J García-Fuster et al FADD monomer (identified with a positive control) ( Figure 1c ). On the other hand, the enzymatic dephosphorylation of FADD with alkaline phosphatase (total homogenate and cytosolic fraction) increased the reactivity of some bands and induced an apparent change in the protein Mr shifting its mobility (51-and 75-kDa forms), indicating that antibody H-181 reacted with FADD independently of the state of protein phosphorylation (Figure 1d ). These results indicated that in brain tissue FADD also has the ability to aggregate (see Siegel et al, 2000) , being mainly expressed as a homo-dimer/trimer. In rat brain (cerebral cortex) and at the subcellular level, FADD was abundantly localized in the cytosol and nucleus and to a lesser extent in membranes, and it was not detected in the cytoskeletal compartment (Figures 1e and 3 ). From these preliminary experiments, the effects of opiate drugs on 51 kDa FADD (antibody H-181) were assessed in the total homogenate of rat brain tissue, except for those of sufentanil that were also quantitated in the different subcellular compartments.
Acute Effects of Opiate Drugs on FADD Immunoreactivity in Rat Brain
The acute treatment with sufentanil (a potent m-opioid receptor agonist; 1-30 mg/kg, s.c., 30 min), compared with vehicle solution administration, induced modest increases (12-22%, p40.05, at low doses) or marked decreases (40-58%, po0.01, at high doses) in the immunodensity of FADD in the rat cerebral cortex (total homogenate) ( Figure 2a) , with a rapid time-course that lasted for about 60 min (Figure 2b) . A similar reduction of FADD (51 kDa) content induced by sufentanil (15 mg/kg) was quantitated in the cortex (30-35%) when a monoclonal antibody (see Figure 1c ) was used as a tool (data not shown). At the subcellular level, sufentanil (15 mg/kg) decreased the content of FADD in the cytosolic (71%) and nuclear (31%) fractions (Figure 3) , indicating that the changes of this protein quantitated in the total homogenate of the cerebral cortex reflected its regulation in the key cellular compartments. Similarly to sufentanil, acute morphine (3-100 mg/kg, i.p., 2 h) also induced bell-shaped dose effects with increases (20-42%, po0.01; 10-30 mg/kg) and decreases (29%, po0.05; 100 mg/kg) in FADD density in the cortex (Figure 4a ). Acute heroin (10 mg/kg, i.p., 2 h) also augmented FADD content in the same brain region (3774%, n ¼ 5, p ¼ 0.002) (data not shown). Pretreatment of rats with naloxone (10 mg/kg) fully prevented the acute inhibition of FADD induced by 15 mg/kg sufentanil (Figure 2c ). The acute treatment with SNC-80 (a selective d-agonist; 10 mg/kg, i.p., 30 min) decreased the immunodensity of FADD in the cortex (56%, po0.001) for more than 1 h (Figure 5a, b) , and this effect was antagonized by the selective d-antagonist naltrindole (5 mg/kg) (Figure 5c ). Treatment with U50488H (a selective k-agonist; 10 mg/kg, i.p., 1 h) also reduced FADD content in the cortex (36%, po0.001) and the effect lasted for more than 2 h (57%, po0.0001) (Figure 6a, b) . This inhibitory effect of U50488H on FADD was blocked by the selective k-antagonist norbinaltorphimine (5 mg/kg) (Figure 6c ). Lower doses of SNC-80 and U50488H (1 and 3 mg/kg) did not alter the content of FADD in the brain (Figures 5a and 6a) .
Effects of Chronic Opiate Drugs, and of Antagonist-Precipitated or Natural Opiate Withdrawal on FADD Immunoreactivity in Rat Brain
Chronic (5 days) treatment with morphine (10-100 mg/kg), compared with saline solution administration, did not alter significantly the immunodensity of FADD in the cerebral cortex (2 h post-treatment) (Figure 4b ), indicating the induction of a marked tachyphylaxis to the repeated doses of the opiate. In morphine-dependent rats, naloxone (2 mg/kg)-precipitated withdrawal (2 h) induced a modest decrease in the density of FADD (13%, p40.05), but the spontaneous opiate withdrawal (24 and 48 h) was associated with a marked and time-dependent downregulation of FADD content in the cortex (32 and 50%, respectively, po0.05) (Figure 4b ).
The repeated treatment (5 days) with SNC-80 (10 mg/kg) or U50488H (10 mg/kg), compared with the corresponding vehicle, did not modify the density of FADD in the cortex (Figures 5d and 6d) , which also suggested the induction of tachyphylaxis to the acute effects of the opiates on this protein. In SNC-80-dependent rats, naltrindole (2 mg/kg)-precipitated withdrawal (2 h) induced a significant reduction of FADD content in the cortex (35%, po0.05) (Figure 5d ). In U50488H-dependent rats, nor-binaltorphimine (2 mg/kg)-precipitated withdrawal (2 h) did not induce significant changes in the density of FADD in the cortex (Figure 6d) .
The various opiate treatments (acute, chronic, and withdrawal effects) did not alter significantly the immunodensity of b-actin, which was used as a negative control (see figures).
Effect of MEK Inhibition on d-Agonist-Induced Downregulation of FADD in Rat Brain
The highly selective MEK1/2 inhibitor, SL 327, was used as a tool to assess the possible involvement of ERK1/2 activation in the in vivo regulation of FADD by the selective d-agonist SNC-80 (Figure 7) . The d-opioid receptor was chosen as a target because it appears to regulate the expression of FADD (tonic inhibition) in the brain (see Discussion).
Pretreatment of rats with SL 327 (20 mg/kg, i.p.) fully prevented the downregulation of FADD content induced by SNC-80 (10 mg/kg, 30 min) both in the cerebral cortex (decrease: 43%, po0.05) and corpus striatum (decrease: 29%, po0.05) (Figure 7a, b) . SL 327 (90 min) alone did not alter the density of FADD (Figure 7a, b) . In both brain regions, SL 327 by itself reduced, as expected, the basal activity of phosphorylated ERK1/2 (p44/42 MAP kinases, 15-46%, po0.05) and augmented that of phosphorylated MEK1/2 (70-109%, po0.01) (this latter effect was probably Figure 4 Acute, chronic, and withdrawal effects of morphine on FADD immunodensity in rat brain (cerebral cortex). (a) Acute dose-response effects. Groups of treatments: saline (C, n ¼ 6), morphine (3-100 mg/kg, i.p., 2 h; n ¼ 4-5). Columns are means7SEM of n experiments per group with an animal per experiment, and expressed as percentage of salinetreated rats. One-way ANOVA detected a significant difference between the groups of treatments (F(4,19) ¼ 12.2, po0.0001): *po0.05; **po0.01 when compared with the saline group (ANOVA followed by Bonferroni's test). (b) Chronic effects of saline (C, n ¼ 9) and morphine (M, 10-100 mg/ kg for 5 days; n ¼ 9) followed by naloxone (Nlx, 2 mg/kg, i.p.; n ¼ 9)-precipitated (2 h) or spontaneous (SW, 24 and 48 h; n ¼ 4-5) opiate withdrawal. Other details as above. ANOVA (F(4,31) ¼ 7.3, po0.005): *po0.05; **po0.01 vs chronic saline; 
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M-J García-Fuster et al mediated by an intra-cascade feedback regulation; see Kolch et al, 2005; Vogel et al, 2005) , without altering the total content of MEK/ERK proteins (Figure 7c, d) . Moreover, SNC-80 increased the phosphorylation of MEK1/2 (150-160%, po0.01) and ERK1/2 (31-51%, po0.05), and pretreatment with SL 327, consequently, blocked the activation of ERK1/2, but not that of MEK1/2 induced by the d-agonist (Figure 7c, d ). In these series of experiments, the content of b-actin remained unchanged after the various treatments (Figure 7a, b) . The inhibition of ERK/MAPK cascade with SL 327 did not alter significantly the abundance of Fas proteins (receptor glycosylated forms and complexes of Fas monomers) (data not shown), excluding alterations in Fas receptor expression as a mechanism behind the reported regulation of FADD in the brain.
Acute, Chronic, and Withdrawal Effects of Opiate Drugs on Caspase-8 and Caspase-3 Immunoreactivities in Rat Brain
The various acute and chronic treatments with opiate drugs (m-, d-, and k-agonists) and the induced opiate withdrawals did not modify significantly the immunodensities of the proforms of caspase-8 (55 kDa) and caspase-3 (32 kDa) in the cerebral cortex (Table 1 and Figure 8) . Moreover, the basal activation and cleavage of caspase-8 (human) and caspase-3 (rat) (about p20 kDa cleavage forms) were not altered by any opiate treatment or withdrawal state in the cortex (see Figure 8a , c for chronic morphine and opiate withdrawal). Another antibody used for the detection of caspase-3 (human) only recognized the 32 kDa proform in brain tissue (see Figure 8b) . Acute and Chronic Effects of the Cannabinoid CB 1 Receptor Agonist WIN 55,212-2 on FADD Immunoreactivity in Rat Brain
To assess whether the stimulation of other inhibitory Gi/o protein-coupled receptors can induce a reduction of FADD in the rat brain, the effects of the cannabinoid CB 1 receptor agonist WIN 55,212-2 were investigated. The CB 1 receptor was chosen because this system, similarly to opiate drugs, has been associated with neurotoxicity and/or apoptosis through the modulation of MAPK pathways (see Downer et al, 2003; Powles et al, 2005) .
The acute treatment of rats with high doses of WIN 55,212-2 (4 and 8 mg/kg, i.p., for 1 h) or the repeated treatment with this agonist (2-8 mg/kg, i.p., for 5 days) (see Moranta et al, 2004) did not significantly alter the immunodensity of FADD in the cerebral cortex (Figure 9 ).
DISCUSSION
FADD protein in rat, mouse, and human brains was recognized as nonphosphorylated (faster-migrating) and phosphorylated (slower-migrating) species (see Zhang and Winoto, 1996; Scaffidi et al, 2000) , indicating that the antibody H-181 (used for quantitative experiments) reacted with FADD independently of the state of protein phosphorylation. The relevance of the 51-kDa FADD form (antibody H-181) was confirmed by use of two different monoclonal antibodies (cf. Figure 1b, et al, 2003a) and the current data demonstrated that the Figure 6 Acute, chronic, and withdrawal effects of U50488H (a selective k-opioid receptor agonist) on FADD immunodensity in rat brain (cerebral cortex). (a) Acute dose-response effects. Groups of treatments: saline (C, n ¼ 7), U50488H (1-10 mg/kg, i.p., 1 h; n ¼ 4). Columns are means7SEM of n experiments per group with an animal per experiment, and expressed as percentage of saline-treated rats. One-way ANOVA detected a significant difference between the groups of treatments (F(3,15) ¼ 11.2, po0.0005): **po0.001 when compared with the saline group (ANOVA followed by Bonferroni's test). (b) Time-course (30-120 min) effects (10 mg/kg; n ¼ 4-6). Other details as above. ANOVA (F(3,14) ¼ 12.8, po0.0005): *po0.05, ***po0.0001 vs control. (c) Antagonism by nor-binaltorphimine (k-selective). Groups of treatments: saline (C, n ¼ 5), U50488H (U, 10 mg/kg, 60 min; n ¼ 4), nor-binaltorphimine (Nbt, 5 mg/kg i.p., 90 min; n ¼ 4) and Nbt + U (n ¼ 5). Other details as above. ANOVA (F(3,14) ¼ 7.1, po0.005): **po0.001 vs control; w po0.01 vs U50488H. (d) Chronic effects of saline (C, n ¼ 5) and U50488H (U, 10 mg/kg for 5 days, n ¼ 5) followed by nor-binaltorphimine (Nbt, 5 mg/kg, i.p.)-precipitated (2 h) opiate withdrawal (n ¼ 5). Other details as above. ANOVA did not detect a significant difference between the groups of treatments. Bottom (a-d): representative immunoblots of FADD for each set of experiments, and the corresponding for b-actin as a loading control (sample: 40 mg protein).
c). Previous results (García-Fuster
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M-J García-Fuster et al proteins that constitute the DISC (Fas, FADD, and caspase-8) are constitutively present in brain tissue. The DISC appears to contain a specific stoichiometric ratio of proteins (3 : 3 : 3), which are organized by the trimeric structure of the preassembled Fas receptor (Siegel et al, 2000) . In fact, mutant (defective) Fas cannot recruit three FADD molecules and consequently do not form a DISC (review in Tibbetts et al, 2003) . In rat brain tissue, only the monomeric form of procaspase-8 was immunodetected as described in other cell systems (see Donepudi et al, 2003) . In contrast, the monomeric form of FADD (about 25 kDa) was not detected in the postnatal (P1-P22) rat cerebral cortex (Cheema et al, 1999) , or it showed a very weak signal in the adult rat cortex (current results). In the human brain, the FADD monomer was readily immunodetected with a species-specific monoclonal antibody (cf. Figure 1c) . Therefore, in the rat brain is mainly expressed as homo-dimer/trimer forms as reported in this study. In line with this, Fas receptor (35 kDa) aggregates of about 110/ 120 kDa (trimers) have been also identified in the rat brain (García-Fuster et al, 2004a) .
The main results indicate that (1) the acute treatments with m-(sufentanil, morphine), d-(SNC-80), and k-(U50488H) opiate agonists induced marked decreases in the density of FADD through the activation of the corresponding opioid receptor; (2) the repeated administration of opiate drugs resulted in the induction of tachyphylaxis to their acute inhibitory effects on FADD; (3) opiate withdrawal in m-and d-opiate-dependent rats was also associated with a reduction in FADD density; and (4) a selective MEK1/2 inhibitor (SL 327) prevented the decrease of FADD induced by SNC-80, demonstrating the involvement of ERK1/2 activation in the in vivo regulation of this protein in the brain.
Concerning the acute effects of opiate drugs, sufentanil and morphine induced bell-shaped dose effects on the immunodensity of FADD (increases and decreases), although the inhibitory effects were more remarkable, as it was the case for SNC-80 and U50488H. In this context, opiate drugs and various apoptotic agents have been shown to induce biphasic effects in multiple biological systems, with moderate stimulatory responses and marked inhibitory effects (Calabrese, 2001a, b) . The present data demonstrate that m-, d-, and k-opioid receptors may all have a role in the acute pharmacologic regulation of FADD, although recent findings indicate a preponderant input of the d-receptor in the functional regulation of this key apoptotic protein in the brain. Thus, it has been observed that in d-opioid receptordeficient mice, but not in m-and k-receptor knockout mice, the basal immunodensity of FADD is increased in the cerebral cortex (48712%, n ¼ 5, po0.01), suggesting the existence of an endogenous opioid tone that, acting on dreceptors, tonically inhibits FADD expression in the brain (García-Fuster et al, 2004b ; submitted for publication). Moreover, it is of interest to note that treatment of rats with the cannabinoid CB 1 receptor agonist WIN 55,212-2, at doses (4 and 8 mg/kg) that induce significant neurochemical effects in the CNS (Moranta et al, 2004) , did not result in decreases of FADD content in the brain. This finding could suggest some specificity of opioid receptors in the modulation of FADD or, at least, that not all Gi/o protein-coupled receptors can mediate the inhibition of this protein in the brain upon receptor stimulation.
In constrast to the acute treatments with m-, d-, and kagonists on FADD (reduced content), the chronic administration (5 days) of morphine, SNC-80, and U50488H resulted in the induction of marked tachyphylaxis to the initial inhibitory effects of the opiates, which most probably reflected the corresponding process of receptor desensitization reported after repeated agonist exposure (Okura et al, 2003; Liu-Chen, 2004; Dang and Williams, 2004) . Notably, in m-and d-, but not in k-, opiate-dependent rats, antagonistprecipitated or spontaneous opiate withdrawal induced a new and sustained inhibitory stimulus on FADD (lasting more than 2 days in the case of morphine withdrawal), which could be related to the large increase in the release of enkephalins (endogenous ligands for m-and d-opioid receptors) observed in the brains of chronic morphinewithdrawn rats (Mas Nieto et al, 2002) , which also displayed higher numbers of c-Fos-positive neurons identified as enkephalinergic neurons (Veinante et al, 2003) .
A relevant finding of this investigation was the identification of a molecular mechanism (activation of ERK1/2 MAPK signaling) responsible for the ability of the d-agonist SNC-80 to decrease FADD content in the brain. Thus, treatment of rats with 20 mg/kg of SL 327 (a dose that selectively blocks MEK1/2 activity and induces significant neurochemical effects in the CNS; see Ferguson and Robinson, 2004) , abolished the decrease in FADD produced by SNC-80 in the cerebral cortex and corpus striatum. Moreover, and as expected, SL 327 was also able to block the activation of ERK1/2, but not that of MEK1/2, induced by SNC-80. These results clearly demonstrated the direct involvement of the two MAPKs (sequential activation of MEK and ERK) in the in vivo regulation of FADD by the opiate agonist. The same molecular mechanism can be postulated for the inhibitory effect of morphine on FADD, since this opiate also activated ERK1/2 in the rat brain and it failed to do so in SH-SY5Y cells after inhibition (PD98059) of MEK1/2 (Ferrer-Alcón et al, 2004) . It should be mentioned that inhibition of MAPK signaling (SL 327) did not modify the various forms of Fas quantitated in the same brain samples, excluding alterations in the density of this receptor in the regulation of FADD.
The reduction of FADD content induced by opiate drugs may be related to the recently uncovered neuroprotective or survival-promoting effects associated with extra-analgesic doses of opiates (acute effects) in various systems (Tegeder and Geisslinger, 2004) Representative immunoblots of (a) human 55 kDa procaspase-8 and Ep20 kDa cleavage form (arrows), (b) human 32 kDa procaspase-3 (arrow), and (c) rat 32 kDa pro-caspase-3 and Ep20 kDa cleavage form (arrows; PC: positive control), as well as the corresponding for b-actin (loading control) protein immunoreactivities in the cerebral cortex of control and morphine-dependent rats (samples: 40 mg protein). Effects of chronic saline (C), chronic morphine (M, 10-100 mg/kg for 5 days), and chronic morphine followed by naloxone (Nlx, 2 mg/kg, i.p.)-precipitated (2 h) or spontaneous (SW, 48 h) opiate withdrawal (see also Table 1 ). and Rao, 2000) or, conversely, to deliver survival signals (eg neurite growth, Desbarats et al, 2003) . In previous studies in rats (Boronat et al, 2001; García-Fuster et al, 2003a , 2004a , heroin/morphine addiction and opiate withdrawal were associated with upregulation of Fas in the brain (ie, increased content of native receptor and complexes of monomers relevant in Fas signaling). In the current study, FADD, the adaptor protein that couples Fas to caspase-8 and transmits the death signal, followed an opposite modulation. Together, the results suggest that possible apoptotic signals engaged by Fas activation (see Tegeder and Geisslinger, 2004; Liao et al, 2005) would be offset by decreased signal transduction through FADD and effector caspases-8/3 (not altered by any opiate treatment). Since the activation of ERK1/2 is crucial for various antiapoptotic mechanisms (Wada and Penninger, 2004) , including protection against Fas-mediated apoptosis (Holmström et al, 1999 (Holmström et al, , 2000 , it is tempting to conclude that opiate drugs (and specifically the d-agonists) could promote survival signals in the brain through inhibition of FADD, which in turn is dependent on the activation of ERK1/2 signaling. In this context, recent studies have shown that activation of d-opioid receptors can protect neocortical neurons from glutamate excitotoxicity (Zhang et al, 2000) and induce other cytoprotective effects (Barry and Zuo, 2005) .
